Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
Fifty-one transfusion-dependent iron-loaded adult patients (38 with thalassemia major) were treated with the orally active iron chelator deferiprone (1,2 dimethyl-3-hydroxypyrid-4-one, L1) at a dose of 75 mg/kg/d (range, 50 to 79). Twenty patients discontinued the drug and five died after a mean of 18.7 months (range, 4 to 35). Of the 20, 5 had arthropathy, 5 had gastrointestinal symptoms, 4 had a rising serum ferritin, 3 had agranulocytosis or neutropenia, 1 had tachycardia, 1 had renal failure, and 1 went abroad. Twenty-six patients continued deferiprone for a mean of 39.4 months (range, 12 to 49). Among these patients, there was no overall significant change in serum ferritin (initial mean, 2,937 microg/L; range, 980 to 5,970; final mean, 2,323 microg/L; range, 825 to 5,970) or in urine iron excretion (initial mean, 31.2 mg/24 h; range, 16.3 to 58. 2; final mean, 32.1 mg/24 h; range, 9.4 to 75.8), implying no overall change in iron stores. When the patients who had received deferiprone for longer than 3 years were considered separately, there was also no significant change in serum ferritin or urinary iron excretion. The initial serum ferritin levels in the 26 patients who continued deferiprone treatment were significantly lower than in those who discontinued the drug (P < .01). The liver iron content in 17 patients who had received deferiprone for 24 to 48 months ranged from 5.9 to 41.2 mg/g dry weight, 50% having levels above 15.0 mg, a level associated with a high risk of cardiac disease due to iron overload. In this study the drug caused fewer side effects and was more effective at maintaining iron status among patients previously well chelated and with lower initial serum ferritin levels.
Hoffbrand
A V
AV
Department of Hematology, The Royal Free Hospital School of Medicine, London, UK.
AL-Refaie
F
F
Davis
B
B
Siritanakatkul
N
N
Jackson
B F
BF
Cochrane
J
J
Prescott
E
E
Wonke
B
B
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000755:Anemia, Sickle Cell / Q000097:blood / Q000150:complications / Q000628:therapy; D001803:Blood Transfusion; D002614:Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015913:Chelation Therapy / Q000009:adverse effects; D003131:Combined Modality Therapy; D000077543:Deferiprone; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000652:urine; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000628:therapy; D008099:Liver / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use*; D013156:Splenectomy; D014168:Transferrin / Q000032:analysis; D065227:Transfusion Reaction; D017086:beta-Thalassemia / Q000097:blood / Q000150:complications / Q000628:therapy
D002614:Chelating Agents; D006454:Hemoglobins; D011728:Pyridones; D014168:Transferrin; D000077543:Deferiprone; D007501:Iron